Grip strength rose 18-21% while 21 kg came off on tirzepatide
In short
Ninety-three men with obesity and testosterone deficiency spent 12 months on weekly tirzepatide, intramuscular testosterone cypionate, and lifestyle coaching centred on resistance exercise and protein intake. Body weight fell 20.9-22.6 kg (18-20%), fat mass fell 16.6-17.1 kg (38-40%), and lean body mass fell 4.0-6.1 kg. Bioimpedance-derived skeletal muscle mass nevertheless rose 1.6-3.7 kg (4-12%) and grip strength rose 5.7-7.1 kg (18-21%). It is an uncontrolled retrospective case series, so no single component can be credited.
The worry that incretin-based weight loss takes muscle with it is well founded. In this record, though, grip strength rose 18-21% while body weight fell about 21 kg. What was done alongside the drug is the whole story.
What was done alongside?
The series covers 93 men with obesity, symptoms of testosterone deficiency and morning total testosterone below 400 ng/dL; 45 had type 2 diabetes and 48 did not. Over 12 months they received weekly tirzepatide, intramuscular testosterone cypionate, and lifestyle coaching focused on resistance exercise and protein intake, with weekly behavioural support.
Body composition was measured by multifrequency bioelectrical impedance and grip strength by dynamometry at baseline and at 3, 6 and 12 months.
Lean mass fell but muscle mass rose?
At 12 months body weight was down 20.9-22.6 kg (18-20%) and fat mass down 16.6-17.1 kg (38-40%). Lean body mass fell 4.0-6.1 kg. So far this is the picture everyone fears.
From the same scans, skeletal muscle mass rose 1.6-3.7 kg (4-12%) and grip strength rose 5.7-7.1 kg (18-21%). The authors read this as disproportionate loss of non-muscle lean tissue such as fluid and connective tissue. Lean body mass is one bucket, and it is not a synonym for muscle.
What happened to the bloodwork?
Among participants with type 2 diabetes, HbA1c fell from 10.1% to 5.8%. LDL cholesterol dropped 20% and high-sensitivity CRP 43-53%, while PROMIS physical and mental health scores improved 13-16%.
This is a retrospective case series from a single clinic with no control group. Drug, hormone, exercise, protein and behavioural support were applied together, and the authors state outright that the design precludes attributing the result to any component. Body composition came from bioimpedance rather than DXA, and testosterone was prescribed and supervised after a deficiency diagnosis. Nothing here supports copying the stack on your own.
What it means for your Muscle Index
Muscle Index rewards a lower body weight through the coefficient, but only if the Big 3 total holds. The usable hint in this record is not the weight loss; it is that resistance work and protein stayed attached to it. Change the weight field while the lifts hold and the score rises. Keep logging your lifts through a cut and the difference shows up on the graph.
For other angles on the same problem, see GLP-1 use collapses absolute protein intake, the hypothesis that muscle lost in a cut worsens blood glucose and 36 lifting sessions did not stop 3.4 kg of lean loss.
Frequently asked questions
Does incretin-based weight loss always cost muscle?
Lean body mass did fall by 4.0-6.1 kg in this series. Over the same 12 months, however, bioimpedance-derived skeletal muscle mass rose 1.6-3.7 kg and grip strength rose 18-21%, which the authors attribute to disproportionate loss of non-muscle lean tissue.
How much weight was lost?
Body weight fell 20.9-22.6 kg (18-20%) and fat mass 16.6-17.1 kg (38-40%) over 12 months. Among participants with type 2 diabetes, HbA1c fell from 10.1% to 5.8%.
How can muscle mass rise while lean mass falls?
Lean body mass includes fluid and connective tissue as well as muscle. In this series the non-muscle portion of lean tissue fell much faster, so total lean mass declined while the skeletal muscle estimate increased.
Can the result be credited to the drug?
No. Tirzepatide, testosterone, resistance exercise, protein coaching and behavioural support were applied simultaneously in an uncontrolled retrospective case series, and the authors state that individual contributions cannot be separated.
Should anyone copy the testosterone part?
No. Participants had a diagnosed deficiency with morning total testosterone under 400 ng/dL and were treated under medical supervision. Self-administration by someone without a deficiency is not supported by this study.
Source: PubMed